BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sahota T, Danhof M, Della Pasqua O. Pharmacology-based toxicity assessment: towards quantitative risk prediction in humans. Mutagenesis 2016;31:359-74. [PMID: 26970519 DOI: 10.1093/mutage/gev081] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Khurm M, Wang X, Zhang H, Hussain SN, Qaisar MN, Hayat K, Saqib F, Zhang X, Zhan G, Guo Z. The genus Cassia L.: Ethnopharmacological and phytochemical overview. Phytother Res 2020. [PMID: 33617115 DOI: 10.1002/ptr.6954] [Reference Citation Analysis]
2 Fiori GML, Basso FG, Porto GS. Cooperation in R&D in the pharmaceutical industry: Technological and clinical trial networks in oncology. Technological Forecasting and Social Change 2022;176:121426. [DOI: 10.1016/j.techfore.2021.121426] [Reference Citation Analysis]
3 Allegra S, De Francia S, Cusato J, Pirro E, Massano D, Piga A, D'Avolio A. Deferasirox pharmacokinetic and toxicity correlation in β-thalassaemia major treatment. J Pharm Pharmacol 2016;68:1417-21. [PMID: 27672004 DOI: 10.1111/jphp.12638] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
4 Ruzzo A, Graziano F, Galli F, Galli F, Rulli E, Lonardi S, Ronzoni M, Massidda B, Zagonel V, Pella N, Mucciarini C, Labianca R, Ionta MT, Bagaloni I, Veltri E, Sozzi P, Barni S, Ricci V, Foltran L, Nicolini M, Biondi E, Bramati A, Turci D, Lazzarelli S, Verusio C, Bergamo F, Sobrero A, Frontini L, Menghi M, Magnani M. Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients. Br J Cancer 2017;117:1269-77. [PMID: 29065426 DOI: 10.1038/bjc.2017.289] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
5 Dubois VF, Smania G, Yu H, Graf R, Chain AS, Danhof M, Della Pasqua O; Cardiovascular Safety Project Team., TI Pharma PKPD Platform. Translating QT interval prolongation from conscious dogs to humans. Br J Clin Pharmacol 2017;83:349-62. [PMID: 27614058 DOI: 10.1111/bcp.13123] [Cited by in Crossref: 4] [Article Influence: 0.7] [Reference Citation Analysis]
6 Batista D, Romáryo Duarte da Luz J, Evellyn Silva Do Nascimento T, Felipe de Senes-Lopes T, Araújo Galdino O, Victor E Silva S, Pinheiro Ferreira M, Arrison Dos Santos Azevedo M, Brandão-Neto J, Araujo-Silva G, López JA, das Graças Almeida M. Licania rigida leaf extract: Protective effect on oxidative stress, associated with cytotoxic, mutagenic and preclinical aspects. J Toxicol Environ Health A 2021;:1-15. [PMID: 34789080 DOI: 10.1080/15287394.2021.2002744] [Reference Citation Analysis]
7 Shakya A, Chaudhary SK, Bhat HR, Ghosh SK. Acute and sub-chronic toxicity studies of Benincasa hispida (Thunb.) cogniaux fruit extract in rodents. Regul Toxicol Pharmacol 2020;118:104785. [PMID: 32976857 DOI: 10.1016/j.yrtph.2020.104785] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
8 Smit IA, Afzal AM, Allen CHG, Svensson F, Hanser T, Bender A. Systematic Analysis of Protein Targets Associated with Adverse Events of Drugs from Clinical Trials and Postmarketing Reports. Chem Res Toxicol 2021;34:365-84. [PMID: 33351593 DOI: 10.1021/acs.chemrestox.0c00294] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
9 Allegra S, De Francia S, De Nicolò A, Cusato J, Avataneo V, Manca A, Antonucci M, D’avolio A. Effect of Gender and Age on Voriconazole Trough Concentrations in Italian Adult Patients. Eur J Drug Metab Pharmacokinet 2020;45:405-12. [DOI: 10.1007/s13318-019-00603-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 van den Brink W, Emerenciana A, Bellanti F, Della Pasqua O, van der Laan JW. Prediction of thyroid C-cell carcinogenicity after chronic administration of GLP1-R agonists in rodents. Toxicol Appl Pharmacol 2017;320:51-9. [PMID: 28213092 DOI: 10.1016/j.taap.2017.02.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
11 White PA, Johnson GE. Genetic toxicology at the crossroads-from qualitative hazard evaluation to quantitative risk assessment. Mutagenesis 2016;31:233-7. [PMID: 27000791 DOI: 10.1093/mutage/gew011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
12 Emmerich CH, Gamboa LM, Hofmann MCJ, Bonin-Andresen M, Arbach O, Schendel P, Gerlach B, Hempel K, Bespalov A, Dirnagl U, Parnham MJ. Improving target assessment in biomedical research: the GOT-IT recommendations. Nat Rev Drug Discov 2021;20:64-81. [PMID: 33199880 DOI: 10.1038/s41573-020-0087-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
13 Gayvert KM, Madhukar NS, Elemento O. A Data-Driven Approach to Predicting Successes and Failures of Clinical Trials. Cell Chem Biol 2016;23:1294-301. [PMID: 27642066 DOI: 10.1016/j.chembiol.2016.07.023] [Cited by in Crossref: 57] [Cited by in F6Publishing: 42] [Article Influence: 9.5] [Reference Citation Analysis]
14 Tosca EM, Bartolucci R, Magni P, Poggesi I. Modeling approaches for reducing safety-related attrition in drug discovery and development: a review on myelotoxicity, immunotoxicity, cardiovascular toxicity, and liver toxicity. Expert Opin Drug Discov 2021;:1-26. [PMID: 34181496 DOI: 10.1080/17460441.2021.1931114] [Reference Citation Analysis]